Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43575
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | VAN DER SPEETEN, Kurt | - |
dc.contributor.author | Kusamura, Shigeki | - |
dc.contributor.author | Villeneuve, Laurent | - |
dc.contributor.author | Piso, Pompiliu | - |
dc.contributor.author | Verwaal, Vic J. | - |
dc.contributor.author | Gonzalez-Moreno, Santiago | - |
dc.contributor.author | Glehen, Olivier | - |
dc.date.accessioned | 2024-08-19T12:28:16Z | - |
dc.date.available | 2024-08-19T12:28:16Z | - |
dc.date.issued | 2024 | - |
dc.date.submitted | 2024-08-19T12:02:04Z | - |
dc.identifier.citation | Annals of surgical oncology, | - |
dc.identifier.uri | http://hdl.handle.net/1942/43575 | - |
dc.description.abstract | This manuscript reports the results of an international consensus on technologies of hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) performed with the following goals: To provide recommendations for the technological parameters to perform HIPEC. To identify the role of heat and its application forms in treating peritoneal metastases. To provide recommendations regarding the correct dosimetry of intraperitoneal chemotherapy drugs and their carrier solutions. To identify for each intraperitoneal chemotherapy regimen the best dosimetry and fractionation. To identify areas of future research pertaining to HIPEC technology and regimens. This consensus was performed by the Delphi technique and comprised two rounds of voting. In total, 96 of 102 eligible panelists replied to both Delphi rounds (94.1%) with a consensus of 39/51 questions on HIPEC technical aspects. Among the recommendations that met with the strongest consensus were those concerning the dose of HIPEC drug established in mg/m2, a target temperature of at least 42 degrees C, and the use of at least three temperature probes to pursue hyperthermia. Ninety minutes as the ideal HIPEC duration seemed to make consensus. These results should be considered when designing new clinical trials in patients with peritoneal surface malignancies. | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.rights | Society of Surgical Oncology 2024 | - |
dc.subject.other | Peritoneal Metastases | - |
dc.subject.other | Cytoreductive Surgery | - |
dc.subject.other | Intraperitoneal Chemotherapy | - |
dc.subject.other | Hyperthermia | - |
dc.title | The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: HIPEC Technologies | - |
dc.type | Journal Contribution | - |
local.format.pages | 21 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | van der Speeten, K (corresponding author), Ziekenhuis Oost Limburg, Dept Surg Oncol, Genk, Belgium.; van der Speeten, K (corresponding author), Univ Hasselt, BIOMED Res Inst, Fac Life Sci, Hasselt, Belgium. | - |
dc.description.notes | kurt.vanderspeeten@zol.be | - |
local.publisher.place | ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.status | Early view | - |
dc.identifier.doi | 10.1245/s10434-024-15513-4 | - |
dc.identifier.pmid | 39037523 | - |
dc.identifier.isi | 001274309900005 | - |
local.provider.type | wosris | - |
local.description.affiliation | [van der Speeten, Kurt] Ziekenhuis Oost Limburg, Dept Surg Oncol, Genk, Belgium. | - |
local.description.affiliation | [van der Speeten, Kurt] Univ Hasselt, BIOMED Res Inst, Fac Life Sci, Hasselt, Belgium. | - |
local.description.affiliation | [Kusamura, Shigeki] Fdn IRCCS Ist Nazl Tumori, Dept Surg Oncol, PSM unit, Milan, Italy. | - |
local.description.affiliation | [Villeneuve, Laurent; Glehen, Olivier] Ctr Hosp Lyon sud, Dept Surg Oncol, Lyon, France. | - |
local.description.affiliation | [Piso, Pompiliu] Hosp Barmherzige Bruder, Dept Gen & Visceral Surg, Regensburg, Germany. | - |
local.description.affiliation | [Verwaal, Vic J.] Syddansk Univ, Peritoneal Surface Malignancy & HIPEC Inst Reg Sun, Odense, Sweden. | - |
local.description.affiliation | [Gonzalez-Moreno, Santiago] Univ Texas MD Anderson Canc Ctr, Calle Arturo Soria 270, Madrid 28033, Spain. | - |
local.uhasselt.international | yes | - |
item.fulltext | With Fulltext | - |
item.contributor | VAN DER SPEETEN, Kurt | - |
item.contributor | Kusamura, Shigeki | - |
item.contributor | Villeneuve, Laurent | - |
item.contributor | Piso, Pompiliu | - |
item.contributor | Verwaal, Vic J. | - |
item.contributor | Gonzalez-Moreno, Santiago | - |
item.contributor | Glehen, Olivier | - |
item.accessRights | Restricted Access | - |
item.fullcitation | VAN DER SPEETEN, Kurt; Kusamura, Shigeki; Villeneuve, Laurent; Piso, Pompiliu; Verwaal, Vic J.; Gonzalez-Moreno, Santiago & Glehen, Olivier (2024) The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: HIPEC Technologies. In: Annals of surgical oncology,. | - |
crisitem.journal.issn | 1068-9265 | - |
crisitem.journal.eissn | 1534-4681 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies_ HIPEC Technologies.pdf Restricted Access | Early view | 631.28 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.